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ABSTRACT
Naturally arising CD4CD25 regulatory T cells (Tregs) have the potential to suppress aberrant immune
responses and to regulate peripheral T-cell homeostasis. In murine models of bone marrow transplantation,
Tregs promote donor bone marrow engraftment and decrease the incidence and severity of graft-versus-host-
disease without abrogating the beneficial graft-versus-tumor immunologic effect. These findings, in concert
with observations that Tregs in mice and humans share phenotypic and functional characteristics, have led to
active investigations into the use of these cells to decrease complications associated with human hematopoietic
cell transplantation. Early human studies suggest that an imbalance of Tregs and effector T cells may
contribute to the development of graft-versus-host-disease. However, the mechanisms of immunoregulation,
in particular the allorecognition properties of Tregs, their effects on and interaction with other immune cells,
and their sites of suppressive activity, are not well understood. In this review, we discuss the current knowledge
of Treg biology and the potential therapeutic strategies and barriers of Treg immunotherapy in human
hematopoietic cell transplantation.
© 2006 American Society for Blood and Marrow Transplantation
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Studies of T-cell mediated immunoregulation
rovide crucial insights into the immune system’s task
f balancing immunologic self-tolerance while pre-
erving tumor and microbial immunity. Regulatory
or suppressor) T cells have emerged as a key cellular
omponent that mediates this process. In recent years,
he discovery of cell surface markers and intracellular
olecules that appear phenotypically and functionally
peciﬁc for regulatory T cells fueled interest in re-
valuating the role of these cells in the regulation of
elf-tolerance, autoimmunity, tumor and microbial
mmunity, and alloresponses in solid organ and hema-
opoietic cell transplantation (HCT). These studies
ave led to the characterization of naturally arising
nd inducible populations of allospeciﬁc regulatory
cells, which hold the potential for the therapy of
utoimmune diseases and transplantation complica-
ions. In this review, we focus on the science and the alinical implications of naturally arising regulatory
cells, herein called Tregs, in HCT.
HENOTYPIC CHARACTERIZATION OF REGULATORY
CELLS
Despite early observations of the potential exis-
ence of regulatory T cells [1-10], the role of a distinct
opulation of T cells that possessed suppressive ca-
acity remained unclear due to the lack of deﬁnitive
nd unequivocal markers for identiﬁcation and limited
tudies on their function at the molecular level. Stud-
es of Tregs in immunodeﬁcient rodent models led to
he recognition of cell surface markers that appeared
peciﬁc for regulatory T cells. In these studies, subsets
f syngeneic CD4 T cells were depleted and the
emaining CD4 cells were transferred into lym-
hopenic hosts and evaluated for the development of
utoimmunity [6,7,11]. In 1995, Sakaguchi et al.
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V. H. Nguyen et al.996eported a key surface marker, the interleukin-2 (IL-2)
eceptor -chain, also known as CD25, on a fraction
f the CD5hi and CD45RBlo subsets of CD4 T cells
11], which were previously demonstrated to have sup-
ressor function [6,7]. In the mouse, CD25 T cells
omprise 5-10% of peripheral CD4 T cells; in hu-
ans, this fraction is slightly smaller. The transfer of
D25-depleted CD4 T cells into athymic nude mice
ed to more systemic and lethal multiorgan autoimmune
yndromes. On a per-cell basis, CD4CD25 T cells
ere more potent than CD5hi or CD45RBlo T cells in
reventing the incidence and severity of autoimmunity
11]. Protection from autoimmunity with the transfer of
D4CD25 T cells has also been reported in the
eonatal thymectomy and diabetic-prone mouse models
12-15].
However, expression of CD25 is not speciﬁc to reg-
latory T cells, because all T cells upregulate CD25
evels upon activation. In humans and mice, the distinc-
ion between activated effector T cells and naturally
rising regulatory T cells has been the constitutive
xpression of CD25 at high levels in the latter. This
remise is used currently to isolate regulatory T cells
or functional in vitro assays and adoptive transfer
tudies.
The recent identiﬁcation of the forkhead tran-
cription factor, Foxp3, as a speciﬁc marker of Tregs
see below) better deﬁnes the regulatory subset of
D4 T cells from activated effector T cells. In mice,
oxp3 mRNA is expressed by most peripheral CD4
cells that expresses high levels of CD25 (up to 96%;
guyen V, unpublished observations). The smaller
raction of regulatory T cells that are found in the
D4CD25int subset also expresses Foxp3 (40-65%);
owever, their suppressive function is signiﬁcantly
ower and may be attributable to a mixture of regula-
ory and activated T cells (Nguyen V, unpublished
bservations). Activation of CD4CD25 T cells
oes not lead to Foxp3 expression. However, Foxp3 is
lso found in subsets of CD4CD25 populations
ith suppressor function in vitro and in vivo [16].
n humans, aside from the homeostatic level of
D4CD25 regulatory T cells generated from the
hymus, peripheral CD4CD25 T cells that are ac-
ivated express CD25 and develop a regulatory or an
ffector function; the suppressor activity of the regu-
atory cell subset is associated with Foxp3 expression
17]. However, recent studies have shown that Foxp3
xpression in and of itself may not confer regulatory
unction [18,19]. In the peripheral blood of normal
onors, up to 96% of CD4CD25hi T cells expressed
OXP3, whereas 22-47% of CD4CD25int T cells
tained positive for Foxp3 by ﬂow cytometry [20]. In
ggregate, these ﬁndings support the continued use of
D25hi as a reliable marker for Tregs in functional
tudies for the present time. Although Foxp3 is more
peciﬁc for Tregs, given its intranuclear localization, phe use of Foxp3 is limited to nonfunctional assays
uch as ﬂow cytometry and immunohistochemistry.
Further phenotypic segregation of murine
D4CD25 cells showed that high expression of
urface markers CD103 [21,22], integrin-(E)7 [23],
r CD62L [24-26] may lead to increased levels of
uppression. Studies of these surface markers to date
ave been limited to several disease models in the
odent and have not been systematically evaluated in
umans. Recent reports have shown that 2 different
urface markers, CD27 [27,28] and CD44act [29], dis-
riminate highly suppressive subsets of human
D4CD25 T cells and may therefore allow further
nrichment for potent Tregs for clinical studies.
UNCTIONAL CHARACTERIZATION OF REGULATORY
CELLS
The mechanism of Treg suppression has mostly
een studied in mice and remains unclear. However,
he following conclusions are well accepted. Tregs
equire T-cell receptor (TCR) ligation by antigen-
peciﬁc or polyclonal stimuli for activation [30,31].
heir activation requires minimal stimulation due to
igh TCR sensitivity relative to CD25 T cells (up to
00-fold lower peptide concentration). Once acti-
ated, Tregs are able to suppress without regard to
ntigen speciﬁcity [30,32]. This ﬁnding has important
mplications in transplantation because histocompati-
ility between Tregs and their effector T-cell (Tcon)
arget may not be necessary for effective suppression.
eripheral Tregs are well differentiated and therefore
re able to suppress upon encountering speciﬁc anti-
ens [30]. Thus, freshly isolated Tregs from naive
ice or human donors are able to suppress upon
timulation by antigens. In vitro, Tregs are anergic to
ntigenic stimulation; the anergic state corresponds to
heir suppressive activity [30]. Thus, breaking the an-
rgic state with high-dose exogenous IL-2 or CD28
timulation leads to proliferation but loss of suppres-
ive activity. This latter strategy [30,31] or stimulation
f Tregs with lipopolysaccharide [33] is used to ex-
and Tregs. With the removal of these exogenous
timuli before in vitro or in vivo studies, the expanded
regs revert to the anergic state, with a reported
ncreased suppressive potency compared to their pre-
ious state [33,34]. In vivo, Tregs proliferate under
teady state and in response to local antigenic stimuli
n normal unmanipulated or lymphopenic mice from
he same genetic background [35-39]. In vivo dynam-
cs of Tregs in the allogeneic setting have not been
ell studied. In a major-mismatched bone marrow
ransplantation (BMT) murine model, adoptively
ransferred Tregs proliferate early after infusion.
hey colocalize with effector T cells in secondary
ymphoid organs and retain prolonged suppressor ca-
acity [40,41].
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Role of Tregs in HCT 997The thymus generates mature CD4CD25
regs with the natural ability to suppress self-reactive
cells [42-47]. This process requires high avidity
nteraction of their TCRs with self-peptide/major his-
ocompatibility complex (MHC) [46] or class II MHC
olecules [42] and IL-2/IL-2 receptor  (IL-2R)
ignaling [48,49] and interaction with mature den-
ritic cells (DCs) [50] via CD28 signaling [51]. The
oxp3 transcription factor is also required to generate
D4CD25Tregs [43,44]; however, the mechanism
y which this occurs remains unclear. In the periph-
ry, Tregs can also be generated from CD4CD25
cells [17,52,53]. However, their phenotype and
unction compared with those of thymus-derived
regs are not well studied.
An array of molecules has been studied and impli-
ated in the mechanism of Treg generation and sup-
ression (Fig. 1). Among them, the major molecules
nclude the transcription factor Foxp3, cytokines and
A
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igure 1. Proposed mechanisms of regulatory T-cell (Treg)-med
ctivation requires interaction of the T-cell receptor (TCR) wit
ntigen-presenting cells (APCs). Once activated, Tregs exert their
r conventional T cells (Tcon) or through APC through costimulat
pregulate the enzyme indoleamine 2,3-dioxygenase (IDO), leadin
eduction of effector T cell activation and function. (B) Resistanc
oll-like receptors (TLRs) on APCs. Interleukin-6 (IL6) and other
con, providing effector signals that override the suppressive effects of Their receptors (IL-2/IL-2R, IL-10), signaling factors
CTLA-4, glucocorticoid-induced tumor necrosis fac-
or receptor family-related gene [GITR], CD28/B7,
ransforming growth factor  [TGF-]), Toll-like re-
eptors (TLRs), and homing markers (CD62L and
CR4,5,6,7,8).
ranscription Factor
Forkhead transcription factor 3. In mouse models,
xpression of Foxp3, a forkhead transcription factor, is
equired for the thymic development and function of
D4CD25 regulatory T cells [16,43,44]. Expres-
ion of Foxp3 is speciﬁc for CD4CD25 regulatory
cells [43]. Activation of CD4CD25 T cells in-
reases Foxp3 expression. In contrast, activated effec-
or T cells, which upregulate CD25, do not express
oxp3. Retroviral-mediated ectopic expression of Foxp3,
owever, induces expression of CD25, CTLA-4, GITR,
con
CR
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uppression and resistance. (A) Treg-mediated suppression. Treg
major histocompatibility class (MHC)-antigen (Ag) complex on
sor function, either directly through cell-cell contact with effector
he CTLA-4 and CD80/86 signaling pathway. Activated APCs may
yptophan catabolism and metabolite production with subsequent
reg suppression. Infection or inﬂammation leads to activation of
molecules produced by activated APCs interact with receptors onT
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V. H. Nguyen et al.998nd CD103 [44] and suppressor function in
D4CD25 T cells [43,44]. Mice deﬁcient in Foxp3
ack regulatory T cells and develop a lethal lymphopro-
iferative disease characterized by wasting and multior-
an autoimmunity. Adoptive transfer of CD4CD25
egulatory T cells from normal mice rescues Foxp3-
eﬁcient mice from the disorder. Interestingly, a similar
ymphoproliferative syndrome, called IPEX (immune
ysregulation, polyendocrinopathy, enteropathy, and x-
inked) is seen in humans with mutations in the gene
OXP3 [54-56]. Based on consistent ﬁndings in mice
nd humans, Foxp3 is considered the “master regulator”
f CD4CD25 regulatory T cells.
ytokines
Interleukin-2/interleukin-2 receptor. IL-2 signaling
s required for CD4CD25 T-cell generation and
ediated suppression [48,57]. Mice with IL-2 or
L-2R deﬁciency develop severe autoimmunity due to
reduction in CD4CD25 regulatory T cells. Au-
oimmune response is prevented with the infusion of
D4CD25 T cells from normal syngeneic mice
48,49].
Interleukin-10. The role of IL-10 in Treg-medi-
ted suppression is controversial due to conﬂicting
ndings from in vitro versus in vivo studies and across
ifferent murine autoimmune and transplantation tol-
rance models [58]. In vitro studies have shown that
reg-mediated suppression is independent of IL-10.
n vivo, IL-10 produced by donor Tregs are important
n controlling graft-versus-host disease (GVHD) in
ajor MHC-mismatched BMT [59] and autoimmune
olitis [60]. However, autoimmune gastritis can be
uppressed independent of IL-10 [61]. The selective
equirement of IL-10 for suppression in different
odels suggests that Tregs exert their function by
everal mechanisms, which may be based on the local
timulation and site of regulation.
ignaling Molecules
CTLA-4. CTLA-4 is a negative regulator of naive
cells and is upregulated upon T cell activation [62].
owever, on murine CD4CD25 T cells, CTLA-4
s constitutively expressed and provides activating sig-
als in Treg-mediated suppression [13,63,64]. Their
xpression appears to be controlled by Foxp3 [44].
nti–CTLA-4 blockade with monoclonal antibodies
brogates protection from colitis in the murine model
f inﬂammatory bowel disease [63] and leads to auto-
mmune diseases in normal mice [64]. However,
D4CD25 T cells from CTLA-4/ mice are able
o suppress in vitro, suggesting that CTLA-4 may be
nly one of several key molecules involved in Treg-
ediated suppression. Signaling through the CTLA-4
athway in Tregs may initiate tryptophan catabolism
y upregulation of enzyme indoleamine 2,3-dioxyge- ease in DCs [65], leading to tryptophan depletion or
n increase in tryptophan catabolites that impair ef-
ector T-cell proliferation and inhibit the production
f proinﬂammatory cytokines [66].
The role of CTLA-4 in human Treg-mediated
uppression is less well deﬁned and appears to be less
mportant [67]. A recent study has shown the inhibi-
ory role of Tregs on DC maturation, which leads to
nefﬁcient activation of effector T cells, possibly me-
iated through the CTLA-4 pathway [68]. In patients
ith metastatic melanoma, administration of anti–
TLA-4 antibody (MDX-010) leads to increased T-
ell activation without inhibition or depletion of
D4CD25 regulatory T cells [69].
Glucocorticoid-induced tumor necrosis factor receptor
amily-related gene. GITR is highly and constitutively
xpressed on the surface of mouse and human
D4CD25 regulatory T cells. Stimulation of
ITR in vitro or in vivo or the removal of T cells
xpressing high levels of GITR leads to autoimmunity
n normal mice [22,70]. The mechanism by which
ITR signaling attenuates Treg activity is unclear but
ay be due to a dampening of CTLA-4 stimulation
70]. Alternatively, GITR signaling may increase IL-2
esponsiveness in CD4 and CD8 T cells. These
ndings suggest that blockade of GITR signaling may
e a feasible approach to enhance Treg function in
ivo. However, expression of GITR is not exclusive to
D4CD25 Tregs. Other T cells, such as CD8
nd CD4CD25, express GITR at low levels, which
re increased upon activation, but do not have regu-
atory activity. However, a fraction of the peripheral
D4CD25 T-cell population expresses GITR at
igh levels and therefore possesses suppressor func-
ion in the colitis model [71].
CD28/B7. CD28 signaling on CD4CD25
regs abrogates their suppressive capacity [30,31].
7-deﬁcient animals in the nonobese diabetic back-
round have a complete deﬁcit in CD28/CTLA-4
ignaling, leading to signiﬁcant decreases in the num-
er of Tregs in the periphery and accelerated diabetes
nset; transfer of Tregs from control NOD mice
elayed or prevented diabetes, suggesting that this
ostimulatory pathway is important for the generation
nd maintenance of Tregs in this model [13]. B7
ostimulation is also required for the peripheral con-
ersion of murine and human Tregs from naive
D4CD25 [72]. In CD28-deﬁcient animals, thy-
ic generation of Tregs and their peripheral mainte-
ance and survival are impaired, with signiﬁcant de-
reases in Treg number [51]. These ﬁndings have
mportant clinical implications in the treatment of
utoimmunity and transplant rejection.
Transforming growth factor . In vitro data on the
ole of TGF- in Treg function have been conﬂicting
30,31,73]. In multiple in vivo murine studies, how-
ver, TGF- is immunosuppressive by its capacity to
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Role of Tregs in HCT 999uppress CD8 effector T-cell proliferation and func-
ion [74-77]. In addition, TGF- is required for the
xpansion and suppressor function of Tregs [78]. As
oted previously, TGF- induces Foxp3 expression in
D4CD25 T cells in vitro, which acquire regula-
ory function [79,80]. Peripheral conversion of murine
nd human Tregs from naive CD4CD25 by induc-
ion of Foxp3 may therefore be mediated by TGF-
74,80]. This observation suggests that ex vivo con-
ersion of naive CD4CD25 T cells via TGF- on
large scale may be explored in the clinical setting.
Toll-like receptors. TLRs are generally expressed
n mature DCs and recognize conserved pathogen-
ssociated molecular patterns found on most mi-
robes or endogenous molecules released during in-
ammation. In murine studies, ligation of the TLR
ed to production of IL-6 by DCs, which conferred
ffector T-cell resistance toward the suppressive effect
f CD4CD25 Tregs [81]. More recently, evidence
as suggested that Tregs may also mediate suppres-
ion independent of DC participation. In the mouse,
D4CD25 Tregs selectively express TLR-4, -5,
7, and -8 [33]. Upon activation with lipopolysaccha-
ide, a TLR-4 ligand, CD4CD25 T cells prolifer-
te and assume greater suppressor potency in vivo,
roviding protection against a wasting syndrome in-
uced by transfer of naive CD4 T cells into immu-
odeﬁcient mice. In humans, in vitro activation of
LR-8 by natural ligands and synthetic guanosine-
ontaining DNA oligonucleotides leads to the reversal
f Treg suppressor function. Transfer of these TLR-8
timulated Tregs leads to enhanced tumor clearance
82]. Although studies have not evaluated the effect of
LR ligation on Tregs in a physiologic and normal
mmune response, their ﬁndings suggest a therapeutic
otential of TLR ligands in mediating Treg function
n the clinical setting.
oming Molecules
Because of the requirement for cell-cell contact for
reg-mediated suppression, colocalization of Tregs with
ffector T cells and/or an antigen-presenting cell (APC)
ntermediate is crucial. Using 2-photon laser scanning
icroscopy, Tang et al. recently demonstrated colocal-
zation of islet antigen-speciﬁc CD4CD25 T cells
ith Tregs and local DCs in the diabetes-prone NOD
ice. Interestingly, they showed direct and stable inter-
ction between Tregs and DCs, whereas interactions
etween Tcons and Tregs were transient [83]. In auto-
mmune models, the ability of Tregs to mediate diabetes
nset was dependent on their ability to home to and
roliferate in pancreatic draining lymph nodes
25,38,84]. In the antigen-draining lymph node, Tregs
ndergo antigen-speciﬁc proliferation and prevent the
nset of diabetes after transfer into NOD mice. Al-
hough the mechanism by which this occurs remains Inclear, a recent report has suggested that Tregs may
nhibit the differentiation and subsequent upregula-
ion of the chemokine receptor CXCR-3 that is re-
uired for effector T cells to exit secondary lymphoid
rgans and enter inﬂamed tissues [85]. Expression of
he homing molecule CD62L [24,26] on
D4CD25 regulatory T cells conferred protection
romGVHD. These studies suggest the importance of
reg priming for effective Treg suppression. Using
ioluminescence imaging, we reported colocalization
f Treg and effector T cells [40] in secondary lym-
hoid organs. After an initial period of proliferation in
econdary lymphoid organs, Tregs migrate to in-
amed tissues and appear to exert their suppression on
ffector cells at these sites [40]. The ability to change
oming receptors allows Tregs to migrate toward the
ite of inﬂammation [86,87]. Adoptive transfer of
CR5/ Tregs into the murine GVHD model de-
reased protection from lethality, possibly due to im-
aired accumulation of these cells in sites of inﬂam-
ation such as the liver, lung, spleen, and mesenteric
ymph nodes [88]. Together, these ﬁndings support
he importance of Treg localization for function.
VHD AND REGULATORY T CELLS
tudies of Murine GVHD
Regulatory T cells suppress acute GVHD morbidity and
ethality. Mixed lymphocyte reaction studies with
ouse and human cells have deﬁned the ability of
regs to suppress the proliferative response of allo-
eactive CD4 T cells [67,89]. These observations
oupled with ﬁndings of Treg-mediated suppression
n autoimmune diseases [90] and solid organ trans-
lantation [91] prompted several groups to investigate
heir effect in GVHD. In murine models of GVHD,
ransplantation of bone marrow into a lethally irradi-
ted host did not cause GVHD. This may be due to a
ombination of factors, including the small T-cell
raction in the bone marrow, most of which has reg-
latory function [92]. Therefore, transfer of naive do-
or T cells (CD4, CD8, or both) is required to
nduce GVHD in these model systems. The onset and
ourse of GVHD depend on the degree of major and
inor MHC disparity and the T-cell dose. In the
nitial studies, depletion of CD4CD25 T cells from
he donor graft accelerated the GVHD course and
ncreased lethality [93]. These ﬁndings provided evi-
ence for the role of Tregs in mediating GVHD.
hysiologic levels of endogenous CD4CD25
cells may contribute to the development and course
f GVHD; however, their small number is likely in-
ufﬁcient to control the overwhelming alloreactive
-cell response in a major MHC-mismatched BMT
etting. Across minor and major MHC class I and/or
I barriers in various mouse strain combinations,
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V. H. Nguyen et al.1000doptively transferred Tregs with Tcons from the
onor protected lethally irradiated recipients from
VHD morbidity and decreased GVHD-related
ortality [34,59,94,95].
Freshly isolated versus ex vivo expanded regulatory T
ells. Based on the MLR results, most studies have
o-infused freshly isolated Tregs and Tcons at a 1:1
atio to obtain the optimal suppression [59,94,95].
iven the paucity of Tregs, which comprise 5-10% of
D4 T cells, multiple groups have expanded these
ells ex vivo using various strategies including anti-
D3/CD28 monoclonal antibodies with high-dose
L-2 or allogeneic APCs or feeder cells with IL-2.
nder these conditions, Tregs maintain their regula-
ory phenotype and function. Some groups have re-
orted enhanced suppression of GVHD with ex-
anded Tregs [34,95].
Proposed mechanism of GVHD suppression. The
echanism by which Tregs suppress GVHD is not
ell understood. The effect of Tregs on GVHD is
ikely to be early and affects the maturation and ex-
ansion of Tcons. Using bioluminescence imaging,
e found early proliferation of Tregs and their colo-
alization with Tcons in secondary lymphoid organs
n a major MHC-mismatched BMT model [40]. Re-
ipients of Tregs showed decreased Tcon prolifera-
ion at these sites. As described above, Tregs express-
ng CD62Lhi are more potent mediators of GVHD,
resumably due to their ability to migrate to second-
ry lymph nodes, where they are primed and activated
24,26]. The central role of APCs in the induction of
VHD was demonstrated in studies by Shlomchik et
l. [96] and Teshima et al. [97]. Residual host APCs
re required for the induction of acute GVHD by
D8 T cells in the minor MHC-mismatched model
96]. However, alloantigen expression on host epithe-
ial tissues, which are often sites of GVHD, are not
ecessary to trigger acute GVHD [97]. These ﬁndings
nd the recent visualization of Treg-DC stable inter-
ction in autoimmune models [83] further lend cre-
ence to the hypothesis that residual host APCs in
econdary lymphoid organs prime and activate allo-
eactive Tcons and Tregs. However, in the presence
f Tregs, costimulatory molecules, CD80/86, on DCs
re downregulated [68,98], making them ineffective in
ctivating effector T cells. This process may occur
hrough CTLA-4 signaling of Tregs, which initiates
ryptophan catabolism through the induction of in-
oleamine 2,3-dioxygenase in DCs [65] and, hence,
ecrease T-cell activation [99]. IL-10 and TGF-
ave also been implicated in Treg-mediated suppres-
ion in autoimmune models. However, studies in
VHD are limited. Hoffmann et al. showed de-
reased protection from GVHD with Tregs derived
rom IL-10–deﬁcient donors [59]. Tregs are not con-
ned to secondary lymphoid organs. Once activated,
regs proliferate and assume a memory phenotype chat expresses a panel of adhesion and homing mole-
ules required for efﬁcient migration into inﬂamed
ites such as the intestine, liver, and skin [86]. Donor
regs have been detected within target GVHD tissues
Nguyen V, unpublished results). The mechanism of
uppression at these sites of inﬂammation is unclear.
Role of Treg in established GVHD. Studies to date
ave addressed the prevention of GVHD. As such,
regs are co-injected with Tcons at the time of trans-
lantation. The effect of Tregs on evolving or estab-
ished GVHD has not been well studied. A single
tudy by Jones et al. demonstrated in the haploiden-
ical transplantation model the inability of Tregs to
ontrol evolving GVHD when infused 2 days after
nfusion of naive CD4 T cells [95]. However, in this
odel, control animals, which received naive CD4
cells, died within 2 weeks of transplantation. The
lloresponse in this model was very aggressive; hence,
t is unclear if higher doses of Treg or a less potent
D4 T-cell response would show Treg-mediated
uppression to be effective in controlling GVHD. In
he MHC-matched model, CD8-mediated GVHD
ould be suppressed by Tregs infused on day 10 after
ransplantation [95]. In this model, the median sur-
ival was 52 days and 35% of animals were alive at
ay 90. These observations support the notion that
regs can mediate evolving GVHD. These and other
tudies suggest that adoptive transfer of Tregs is most
ffective in the early phases of GVHD and that Tregs
ose their effect in established GVHD when end-
rgan injury has occurred.
tudies of GVHD in Humans
Human Tregs share phenotypic and functional
haracteristics with their mouse counterparts [67,89,
00]. Thus, with encouraging results in murine models
f GVHD, multiple studies have evaluated the role of
regs in the development of GVHD. However, these
tudies are mostly retrospective and address mainly
hronic GVHD (cGVHD). Because Tregs have
learly been shown to suppress acute GVHD
aGVHD) in the mouse, it is unclear whether these
ffects can be translated to the cGVHD setting be-
ause of differences in the pathogenesis of aGVHD
nd cGVHD. In cGVHD, there is a major autoim-
une component in its development. Because of the
bility of Tregs to regulate autoimmunity in multiple
isease models, they also may play a role in the patho-
enesis of cGVHD. Below we summarize the recent
uman studies that evaluated the effect of Tregs in
VHD development. These studies measured the
reg content in the peripheral blood of patients who
nderwent allogeneic HCT. Tregs were isolated by
D4CD25hi expression in the early studies [101-
03]. Foxp3 expression by quantitative polymerase
hain reaction (PCR) was the deﬁning marker for
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Role of Tregs in HCT 1001regs in later studies [104-106]. However, results
rom quantitative reverse transcriptase PCR may not
learly distinguish increased Foxp3 transcript levels on
per-cell basis due to Treg activation from increased
umbers of circulating Tregs.
In an early retrospective study, Stanzani et al.
howed somewhat paradoxically that a higher frequency
f CD25hi T cells in the donor graft was associated with
igher incidences of aGVHD and cGVHD [103]. Clark
t al. found a similar relation when they measured the
D25hi T-cell content in the peripheral blood of pa-
ients 100 days after transplantation [101]. Interest-
ngly, however, the CD4CD25hi T cells were able to
uppress CD4CD25 proliferation in vitro. When
D4CD25hi T cells were quantiﬁed prospectively in
5 patients by another group, there was no statistical
ifference in the absolute CD4CD25hi T-cell numbers
ith respect to the development of aGVHD or cGVHD
102]. The investigators further evaluated the ratio of
ctivated nonregulatory T cells, which express OX40
CD134) to CD4CD25hi T cells. CD134 is a member
f the tumor necrosis factor family, which provides
ostimulatory signals to effector T cells. CD134-ex-
ressing T cells are increased in cGVHD in the hu-
an setting [107]. The CD134/CD25hi ratio was sig-
iﬁcantly higher during active cGHVD when
ompared with patients without cGVHD or cGVHD
fter treatment. These ﬁndings suggest that the bal-
nce between effector and suppressor T cells mediate
mmune responses and therefore is a more physiologic
redictor of the development of GVHD and possibly
ther immunologic complications after transplanta-
ion.
In more recent retrospective studies that identiﬁed
egulatory T cells based on PCR analysis of Foxp3
xpression, patients with GVHD had smaller numbers
f Tregs [105,106]. Miura et al. reported a decrease in
oxp3 levels in the peripheral blood mononuclear
ells of patients with aGVHD and cGVHD [105].
he level of Foxp3 expression, assessed by quantita-
ive PCR, also correlated inversely with the level of
VHD and increased with the resolution of GVHD.
he investigators also found a positive correlation
etween GVHD and decreased Foxp3 expression and
-cell receptor rearrangement excision circles
TREC) levels, with the latter being a surrogate
arker for recent thymic emigrants, suggesting that
he source of Tregs may be derived from the thymus
nd not from an expansion of naive T cells from the
onor graft. Therefore, it is likely that aGVHD dam-
ges the thymus and impairs general immune recon-
titution and Treg regeneration, which may contrib-
te to the development of cGVHD. In contrast to
oxp3 expression, the level of CD25 mRNA was in-
reased in peripheral blood mononuclear cells from
atients with GVHD, consistent with previous studies
101,103]. Interestingly, the ﬁndings in this study ex- lended to patients who had allogeneic or autologous
CT, where, in the latter setting, GVHD was in-
uced by administration of cyclosporine A (CsA),
hich has been shown to disrupt the thymic architec-
ure [108,109]. Zorn et al. has recently published sim-
lar ﬁndings showing a correlation between decreased
oxp3 expression and cGVHD [106]. However, they
id not detect an association between Foxp3 expres-
ion, GVHD, and TREC levels. In both studies,
REC levels were assayed from the total pool of
cells. Further distinction between TRECs from
ffector T cells and Foxp3-expressing T cells may
larify conﬂicting ﬁndings by the 2 studies.
These studies lead to different conclusions based
n the identifying marker for Tregs. Foxp3 expression
ppears more speciﬁc for the regulatory properties of
cells and correlates inversely with the incidence and
everity of GVHD. However, results from a recently
ublished paper showed no difference in Foxp3 levels
n CD4CD25 T cells in patients with or without
VHD [104]. These additional ﬁndings further dem-
nstrate that the analysis of Foxp3 expression in the
D4CD25hi T-cell subpopulation as representative
f Tregs may overlook regulatory T cells that express
ow levels of CD25 or are CD25 or CD8 [19,110].
hus, a possible strategy to overcome these issues is to
easure the ratio of effector T cells to Tregs, with the
atter deﬁned only by Foxp3 expression. A further
aveat is that most human studies evaluate the periph-
ral blood content of Tregs; however, all murine data
o date indicate that Tregs exert their biological ef-
ects in tissues. Rieger and colleagues recently con-
rmed the importance of the balance between Tregs
nd effector T cells in the development of GVHD
111]. The relative reduction of Tregs in the gastro-
ntestinal mucosa of allografted patients, as measured
y the Foxp3/CD8 ratio using immunohistochemi-
al methods, was associated with a higher incidence of
ntestinal GVHD [111].
RAFT-VERSUS-TUMOR AND REGULATORY T CELLS
The importance of the graft-versus-tumor (GVT)
ffect after allogeneic HCT has been well established
n humans [112]. Perhaps most analogous to the mu-
ine models of GVHD induction is the administration
f donor lymphocyte infusions (DLIs) in humans with
elapsed leukemia after allogeneic HCT. The devel-
pment of GVHD after DLI is associated with tumor
learance. However, in a signiﬁcant number of pa-
ients, the GVT is evident without associated GVHD.
he mechanism of this separation of effect by DLI is
ot clear but may be due to preferential recognition of
issue-restricted antigens such as those found on he-
atopoietic cells, which are precursors to leukemia/ymphomas, versus those found on epithelial tissues,
w
b
w
G
m
O
i
a
m
t
a
b
g
m
r
m
s
G
w
w
G
l
l
t
t
c
M
d
e
t
c
t
u
k
t
w
T
c
t
c
a
a
m
w
w
o
m
b
A
T
t
s
m
m
t
w
r
t
T
p
m
t
d
r
i
w
E
B
t
f
a
t

n
g
T
g
c
i
w
d
T
t
T
d
a
t
a
f
m
a
p
r
E
o
l
o
d
m
o
p
h
r
c
t
t
V. H. Nguyen et al.1002hich are targets of GVHD. Kim et al. showed that,
y trapping of T cells in secondary lymphoid tissues
here leukemias and lymphomas primarily reside, the
VT effect occurred efﬁciently without GVHD in a
ajor MHC-mismatch murine BMT model [113].
ther target antigens of DLI have been proposed and
nclude major and minor histocompatibility molecules
nd tumor-speciﬁc markers.
Regulatory T cells control GVHD induction in
urine models of BMT by suppressing the matura-
ion and proliferation of effector T cells, which may
lso be involved in the GVT effect. However, the
ystander suppression effect of Tregs may cause
lobal suppression and therefore negatively affect tu-
or immunity. To date, 3 studies have addressed the
ole of Tregs on the GVT effect in matched and
ismatched MHC transplants in mouse models.
In the MHC-matched setting, Jones et al. demon-
trated the ability of Tregs to suppress CD8-mediated
VHD [95]. Tregs were administered at a 1:3 ratio
ith CD8 T cells 10 days after transplantation,
hen animals have not shown overt clinical signs of
VHD. When transplant recipients were chal-
enged with a host-compatible myeloid leukemia cell
ine (MMCBA6) 1 day before lethal irradiation and
ransplantation, Tregs continued to provide protec-
ion from lethal GVHD and allowed efﬁcient tumor
learance by CD8 T cells. Using a completely
HC-mismatched transplantation model between
onor C57Bl6 and lethally irradiated Balb/c recipi-
nts, Edinger and colleagues found that adoptive
ransfer of donor Tregs effectively decreased the in-
idence and severity of GVHD without abrogating
he GVT response [114]. Two tumor models were
sed. In the ﬁrst model, a host-compatible A20 leu-
emia cell line was injected at the time of transplan-
ation. Tregs were given at a 1:1 ratio with Tcons,
hich consisted of physiologic ratios of CD4:CD8
cells. Tumor clearance was assessed by biolumines-
ence imaging of A20 leukemia cells, which were
ransfected with the luciferase gene. Animals that re-
eived Tregs with the Tcons did not develop GVHD
nd cleared the tumor within 2 weeks. In contrast,
nimals that underwent transplantation with bone
arrow or Tcons alone died from tumor progression,
ith a median survival of 21 days, and from GVHD,
ith a median survival of 8 days, respectively. Similar
bservations were reported with the Bcl-1 lymphoma
odel in which tumor cells were inoculated 9 days
efore transplantation to permit tumor engraftment.
s expected, animals that received only Tregs without
cons died from relapsed disease, consistent with
heir lack of cytolytic function. Trenado et al. showed
imilar outcomes when using the same GVHD/GVT
odel with A20 [115]. However, when using the P815
astocytoma cell line, which leads to subcutaneousumors, Trenado et al. showed that the GVT effect Bas compromised by the presence of Tregs. Mice that
eceived only Tcons efﬁciently cleared the tumor at
he injection site but also developed severe GVHD.
he conﬂicting outcomes of this GVT effect com-
ared with that observed with A20 and Bcl-1 tumors
ay be attributable to donor-recipient variables such as
he Treg/Tcon cell ratio, genetic differences, and con-
itioning regimen, ie, dose of radiation, and tumor-
elated variables such tumor engraftment, growth kinet-
cs, disease burden, and location.
The mechanism by which Tregs suppress GVHD
ithout comprising the GVT effect was evaluated by
dinger and colleagues in the major MHC-mismatch
MT model [114]. Using bioluminescence imaging,
hey found dramatic Tcon expansion within the ﬁrst
ew days of transfer, consistent with induction of
GVHD. Co-transfer of Tregs markedly decreased
his proliferation in secondary lymphoid organs by
90% at day 7, with subsequent decreases in Tcon
umbers at sites of inﬂammation such as the skin and
astrointestinal tract. In vitro analysis of splenic
cons isolated on day 5 from different experimental
roups for their phenotype, activation markers, and
ytokine production has shown that Tregs do not
nhibit activation of Tcons. In addition, co-transfer of
ild-type Tregs and Tcons with deﬁcient perforin or
efective Fas ligand compromised the GVT effect.
he presence of Tregs therefore does not abrogate
he activation of Tcons or their cytolytic response.
he investigators hypothesized that the signiﬁcant
ecrease in Tcon proliferation by Tregs controlled
GVHD, which generally requires a strong alloreac-
ive response. However, this decrease is not complete
nd the remaining donor Tcons are sufﬁcient to ef-
ectively mount a GVT effect [114]. If this proposed
echanism holds true in the clinic, then the effective
pplication of Tregs in human HCT may require
rior reduction of the tumor burden to the level of
esidual disease.
NGRAFTMENT AND REGULATORY T CELLS
Studies in solid organ transplantation have dem-
nstrated the ability of Tregs to induce and maintain
ong-term graft tolerance [116]. In the initial studies
f GVHD in murine models of BMT, co-transfer of
onor Tregs with Tcons did not interfere with bone
arrow engraftment [34,59,114,115]. However, these
bservations for engraftment were indirect and com-
licated by the presence of GVHD. Recent studies
ave shown a facilitating role of Tregs in bone mar-
ow engraftment models [26,29,117,118]. Joffre and
olleagues found that Tregs provided allospeciﬁc pro-
ection of transplanted bone marrow from host rejec-
ion [118]. In their semiallogeneic model of B6 into
6D2-F1, co-transferred B6-derived Tregs, which
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Role of Tregs in HCT 1003ere preactivated with B6D2-F1 APCs, protected
emiallogeneic bone marrow from B6-derived CD4
r CD8 T cells. This protection was signiﬁcantly
ecreased when third-party bone marrow was trans-
lanted, particularly at low doses of Treg, consistent
ith their antigen-speciﬁc suppressor function. In a
ajor MHC-mismatched model (B6 into Balb/c)
MT model, Hanash and Levy demonstrated in-
reased numbers of committed hematopoietic lineage
nd more primitive multipotential progenitor popula-
ions when Tregs were cotransplanted with B6-bone
arrow into sublethally irradiated recipient Balb/c
ice [117]. Mice that received CD4CD25 also
howed comparable engraftment with Tregs; how-
ver, they developed signs of GVHD, ﬁndings that
ere previously shown for CD8 T cells [119,120].
nhanced engraftment with Tregs was further shown
ith increased long-term donor chimerism in animals
hat received Tregs compared with those that received
one marrow transplant only. Importantly, recipients
f Tregs in this model demonstrated tolerance to host
nd donor antigens but mounted responses to third-
arty antigens such as skin allografts and in vitro
olyclonal T- and B-cell stimulation [117].
Current strategies for durable engraftment often
equire transfusions and/or immunosuppressive regi-
ens that are not antigen speciﬁc. These approaches
re associated with an increased risk of alloimmunity
o blood products and opportunistic infections. Find-
ngs of antigen speciﬁcity in Treg-mediated protec-
ion of bone marrow from host rejection support a
otential use of this facilitating subpopulation of
cells to induce speciﬁc and durable bone marrow
ngraftment.
MPACT OF IMMUNOSUPPRESSIVE AGENTS
N REGULATORY T CELLS
echanism of Different
mmunosuppressive Agents
Immunosuppressive agents are an essential com-
onent of the allogeneic HCT regimen. Therefore,
he effect of immunosuppressive drugs on Treg func-
ion is critical. The major immunosuppressants used
n clinical HCT include calcineurin inhibitors FK506
nd CsA, rapamycin (RAPA), and mycophenolate
ofetil acid (MMF). These agents exert their effect on
ifferent levels of T-cell activation and function. The
alcineurin inhibitors FK506 and CsA associate with
he intracellular immunophilin FK506-binding pro-
ein (FKBP12) and the resulting complex speciﬁcally
inds to and inhibits the Ca2/calmodulin-dependent
hosphatase calcineurin [121], a signaling protein re-
uired for transcriptional activation of IL-2 and other
ymphokine genes. Similar to calcineurin inhibitors, tAPA exerts its effect by binding to FKBP12 [122].
owever, in contrast to FK506 and CsA, RAPA does
ot block TCR-induced calcineurin activity. Instead,
APA inhibits the mammalian target of RAPA
mTOR), a serine/threonine protein kinase whose ac-
ivation is required for protein synthesis and cell-cycle
rogression [122,123]. Therefore, RAPA blocks sig-
aling in response to cytokines or growth factors,
hereas FK506 and CsA exert their inhibitory effects
y blocking TCR-induced activation [122]. The active
etabolite of MMF, namely mycophenolic acid, in-
ibits the activity of inosine monophosphate dehydro-
enase, an enzyme responsible for the de novo path-
ay of guanosine nucleotide synthesis in B and T
ymphocytes, and slows down their proliferative re-
ponse.
nimal Models
In animal models of cardiac allograft, RAPA and
MF did not interfere with the development of reg-
latory T cells [124]. Conversely, high doses of FK506
nd CsA seemed to delay or block the development or
unction of Tregs [124,125]. Because IL-2 is required
or the function of Tregs [57,126], the potential
ownregulation of IL-2 gene transcription by CsA
ay interfere with Treg function and expansion. This
ypothesis would explain why IL-2 is necessary in
tudies for long-term allograft survival [127]. The
ddition of immunosuppressive drugs may also pro-
ote induction of Tregs or enhance their activity.
ycophenolate mofetil, administered with the ac-
ive form of vitamin D3, in a murine diabetes model
128], and RAPA, given in combination with anti-
D3 antibodies in normal rats [129], were associ-
ted with increased Treg numbers. In cultures with
L-2, RAPA selectively expanded a population of
D4CD25Foxp3 T cells that could suppress syn-
eneic naive CD4 T cells. More importantly, these
xpanded Tregs prevented pancreatic islet allograft
ejection [130].
Zeiser and colleagues evaluated the effect of CsA,
MF, and RAPA on adoptively transferred donor
regs in an allogeneic GVHD/GVT model [131].
dministration of RAPA or MMF to patients who
nderwent BMT did not interfere with Treg function;
heir survival was similar to that of animals that re-
eived Tregs alone. However, animals given CsA died
ore rapidly from GVHD and had decreases in Treg
umber and Foxp3 expression. These ﬁndings, in con-
ert with in vitro studies in which the functional defect
f CsA-exposed Tregs could be reversed with the
ddition of IL-2, support the critical role of cal-
ineurin-dependent IL-2 production for Treg func-
ion and survival.
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V. H. Nguyen et al.1004uman Studies
Limited studies have evaluated the effect of im-
unosuppressants on human Tregs. In the primary
ixed lymphocyte culture of CD4CD25 effector
cells and CD4CD25 Tregs, addition of CsA had
o effect on CD25 expression or the activation and
ubsequent suppressor function of Tregs [27]. Similar
ndings were observed with RAPA [27]. The role of
mmunosuppressants on alloantigen-driven, expanded
regs was evaluated in a secondary MLR in which
regs previously cultured with CsA or RAPA were
ixed with fresh CD4CD25 T cells. Tregs cul-
ured in the presence of RAPA were 16-fold more
otent suppressors than were those exposed to CsA.
nhanced Treg potency under these conditions was
ue to the capacity of RAPA to preserve the more
otent CD27 Treg subset of CD4CD25 T cells,
hereas CsA decreased this fraction, thereby lowering
he CD27/CD27 ratio of Tregs [27]. When added
o the MLR at day 2, only RAPA-expanded Tregs and
ot CsA-expanded Tregs suppressed ongoing T-cell
lloreactive responses. In contrast to CsA, RAPA did
ot inhibit induction of FOXP3 transcription [132].
hese ﬁndings in concert with observations in the
ouse models suggest that RAPA would increase the
umber and function of Treg in the donor graft and
erhaps decrease GVHD. Alternatively, the addition
f RAPA may permit smaller numbers of Tregs to be
nfused in adoptive transfer therapy.
The effect of T-cell–depleting agents, such as
ntithymocyte globulin and alemtuzumab, on the de-
elopment or function of Tregs after transplantation
as not been studied.
ARRIERS TO THERAPEUTIC APPLICATIONS
F REGULATORY T CELLS
Encouraging preclinical data have set the stage for
he potential therapeutic application of Tregs in pa-
ients. Major hurdles that must be overcome for suc-
essful clinical trials are addressed below.
ype of Transplant
The effect of Tregs on GVHD has been evaluated
ainly in the major MHC-mismatched murine BMT
etting. In humans, this type of transplantation is per-
ormed rarely and is most analogous to the haploiden-
ical setting. Patients undergoing haploidentical trans-
lantation are at high risk for severe GVHD and are
herefore ideal candidates for adoptive transfer of do-
or Tregs. The decrease in severity and/or prevention
f GVHD with Treg inoculation would permit more
idespread use of this strategy due to the high avail-
bility of the donor pool. However, at the current
ime, most human HCTs are performed between
LA-matched donor-recipient pairs. Because Treg ictivation and proliferation are driven by alloantigen
timuli in vivo, it is unclear if the genetic disparity at
he minor loci is sufﬁcient to elicit a suppressive re-
ponse. A single study using matched-MHC trans-
lants in the mouse showed that Tregs provide pro-
ection from CD8-mediated GVHD [95]. Further
tudies are needed to conﬁrm these ﬁndings and to
valuate the effect of various conditioning and prepar-
tive regimens and immunosuppressive programs (see
mpact of Immunosuppressive Agents on Regulatory
cells) on Treg development and function, particu-
arly in the setting of adoptive transfer of Tregs.
ell Purity
CD25hi expression on CD4 T cells is currently
he standard marker for Treg isolation. The intranu-
lear localization of Foxp3 limits its use to nonfunc-
ional studies. To date, magnetic puriﬁcation tech-
iques used for CD34 stem cell enrichment are not
e able to separate CD25hi from CD25lo fractions
133,134]. In addition, the enriched sample gener-
lly contains a small but signiﬁcant fraction of
D4CD25 cells [133]. This is a concern, partic-
larly if the enriched population is expanded ex vivo
efore adoptive transfer. The CD25 fraction, which
epresents effector T cells, has a greater proliferative
apacity in vitro and may therefore increase the non-
egulatory fraction of injected cells. Using this
ethod, only one-third of donor samples generated
otent suppressor function, which was directly corre-
ated with CD25hi purity [133]. High-speed cell sort-
ng addresses these issues to some extent [135] by
roducing more consistent high levels of suppression
rom donor cells [136]. However, the technology is not
eadily available at most transplantation centers. Another
ore practical but important issue is the effect of the
reezing and thawing process on Treg function before
nfusion. This has not been well evaluated.
ell Dose and Source
Most murine studies have shown optimal suppres-
ion of alloresponses when freshly isolated Tregs are
iven at 1:1 ratio with effector T cells. Given the rarity
f Treg in the peripheral blood, obtaining sufﬁcient
regs from the leukapheresis product will be chal-
enging. Protocols using ex vivo CD3/CD28 costimu-
ation with monoclonal antibodies and intermediate- to
igh-dose IL-2 have been successful in expanding large
umbers of polyclonal Tregs, which retained their phe-
otypic features and showed enhanced suppressive func-
ion [133,136]. Because this strategy of expansion has
een applied to other clinical settings, it appears feasible
hat general medical practice standards could be main-
ained.
Other strategies that are currently being explored
nclude using cord blood as a source of Tregs [137];
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Role of Tregs in HCT 1005nducing regulatory function in CD4CD25 T cells,
hich are more abundant [17,138]; and the potential
se of granulocyte colony-stimulating factor (G-CSF)
o mobilize Tregs from the bone marrow [139]. God-
rey et al. found that cord blood contains a population
f CD4CD25 T cells with phenotypic and func-
ional properties similar to those found in the periph-
ral blood. They reported that, when using the mag-
etic puriﬁcation technique, enriched CD4CD25
cells from cord blood produced more consistent
uppressor function than did those derived from the
eripheral blood. This may be due to a greater dis-
inction of CD25 expression between the CD25lo and
D25hi subpopulations in cord blood, thus allowing
or better enrichment. A current limitation with this
trategy is the low availability of HLA-matched cord
lood and the fact that they are cryopreserved upon
cquisition. Another source of Tregs may be gener-
ted in vitro by activation of peripheral blood
D4CD25 with anti-CD3/CD28 antibodies [17].
alker et al. reported that these stimulated cells ex-
ressed Foxp3, which correlated with suppressor func-
ion in vitro. These ﬁndings are in contrast to
D4CD25 T cells in the mouse, which do not
xpress Foxp3 or assume regulatory function upon
ctivation. Data on the regulatory function of this
ubset of cells in vivo remains unknown, however. The
se of G-CSF may also be considered to increase Treg
obilization. Under steady state, human bone mar-
ow contains a large fraction of CD4CD25Foxp3
cells with regulatory function [139]. G-CSF dis-
upts the CXCR4/CXCL12 signaling pathway, which
ormally mediates Treg trafﬁcking into the bone mar-
ow [139], and therefore mobilizes them into the periph-
ral blood for potential extraction during leukapheresis.
IMING OF ADMINISTRATION
The role of Tregs during various phases of the
nﬂammatory process is not entirely clear. Based on
ur previous observations that Tregs mediate the early
con proliferation after transplantation [114], we
howed that Tregs protected animals from lethal
VHD when administered during the initiation and
arly effector phases of aGVHD. Once GVHD is
stablished with evident clinical signs, the effect of
reg protection is markedly diminished [41]. In an
xperimental colitis mouse model, infusion of Tregs
n the setting of active disease provided protection
140]. The difference in Treg response between these
odels may be attributable to several factors including
he systemic nature of aGVHD and the overwhelming
lloresponse associated with it compared with a local
isease with the colitis model. Higher doses of Tregs
ay be able to control the former. How immunosup-
ressive agents affect the Treg response at varioushases of inﬂammation remains unknown and re-
uires investigation.
The role of Tregs in cGVHD has not been well
tudied. Because of differences in the pathogenesis of
GVHD and cGVHD, there are limitations to extrap-
lating ﬁndings from mouse studies of aGVHD. Nev-
rtheless, quantiﬁcation of Tregs in peripheral blood
rom patients undergoing HCT suggests that Tregs
ediate the development of cGVHD [105,106]. Ma-
or differences between aGVHD and cGVHD suggest
hat Tregs may be effective in controlling the latter.
utoimmunity is a component of the development of
GVHD [141]. Chronic GVHD disease is mostly lo-
alized to speciﬁc organs and the initial alloresponse
ppears less robust. Importantly, most patients with
GVHD have full donor chimerism and are therefore
t lower risk for tumor relapse. Together, these ob-
ervations support further investigation in the use of
regs for cGVHD.
UMMARY
CD4CD25 regulatory T cells have emerged
ecently as a potent mediator of aberrant immune
esponses. The mechanism of Treg suppression re-
ains unresolved but likely involves direct interaction
f Tregs with DCs, which leads to a decrease in
ffector T-cell maturation and proliferation. In the
CT setting, Tregs have proved to be effective in
uppressing lethal GVHD. Importantly, this suppres-
ion does not abrogate the beneﬁcial GVT effect in
ost murine models. Moreover, in preliminary stud-
es, donor Tregs promote engraftment and enhance
mmune reconstitution. Whether these encouraging
bservations will be translated into the human setting
emains to be tested. Overcoming the barriers and
nswering the questions addressed in this review will
e important steps in translating ﬁndings in the mice
o human subjects.
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